Clinical Trials Post COVID19; Decentralized Trials, Just-In-Time, Use of AI and Digital Solutions
Moderator: Arturo Loaiza-Bonilla, MD, MSEd, FACP, Vice Chair, Department of Medical Oncology, CTCA, Chief Medical Advisor & Co-Founder, Massive Bio
Panelists: Sundarkia Hill, MS, Director, Precision Enrollment Network, IQVIA;Selin Kurnaz, PhD, Chief Executive Officer & Co-Founder, Massive Bio
It has been widely recognized that COVID19 has led to “democratization” of clinical trial conduct with increase incorporation of telemedicine and virtual visits, allowance of local and less frequent testing including imaging, lower administrative burden, allowing drugs to be self-administered by patients and less stringent follow-up restrictions. This may lead to a technological revolution in the conduct of clinical trials with an emphasis on patient preference and safety while preserving scientific integrity. The audience will be able to learn further about novel technologies around decentralized clinical trials, ‘Just-In-Time (JIT) activation, a NASA-style Clinical Trial Mission Control Center, as will have the opportunity to learn how different stakeholders are adapting to recent FDA policies and regulations for their R&D post COVID19.